85/100 · Critical
Manufactured by Lannett Company, Inc.
Verapamil Hydrochloride Adverse Events: High Serious Reaction Rate
13,321 FDA adverse event reports analyzed
Last updated: 2026-05-12
VERAPAMIL HYDROCHLORIDE is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Lannett Company, Inc.. Based on analysis of 13,321 FDA adverse event reports, VERAPAMIL HYDROCHLORIDE has a safety score of 85 out of 100. This score indicates a relatively favorable safety profile, with fewer or less severe adverse events compared to many other tracked medications. The most commonly reported adverse reactions for VERAPAMIL HYDROCHLORIDE include DYSPNOEA, NAUSEA, DRUG INTERACTION, DIZZINESS, HYPOTENSION. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for VERAPAMIL HYDROCHLORIDE.
Verapamil Hydrochloride has a safety concern score of 85 out of 100, placing it in the high concern category based on analysis of FDA adverse event data. The FDA has received approximately 13,321 adverse event reports for this medication, which is primarily manufactured by Lannett Company, Inc..
The most commonly reported adverse events include Dyspnoea, Nausea, Drug Interaction. Of classified reports, 90.3% were designated as serious by the FDA, meaning they involved hospitalization, disability, or other significant medical outcomes. High incidence of serious reactions such as respiratory issues, cardiovascular events, and drug interactions.
A significant number of reports involve falls and syncope, indicating potential risk of falls and dizziness. Reports of severe gastrointestinal issues like diarrhea and abdominal pain are common.
Patients taking Verapamil Hydrochloride should monitor for the commonly reported side effects and contact their healthcare provider if they experience any unusual symptoms. Verapamil Hydrochloride can cause significant drug interactions and should be used with caution, especially with other cardiovascular medications. This analysis is based on voluntary FDA adverse event reports and should not replace professional medical advice.
Verapamil Hydrochloride received a safety concern score of 85/100 (high concern). This is based on a 90.3% serious event ratio across 4,222 classified reports. The score accounts for 13,321 total adverse event reports and 100 distinct reaction types. This high score reflects a significant proportion of serious adverse events in the reporting data.
Adverse event reports by sex: Female: 2,200, Male: 1,461, Unknown: 24. The most frequently reported age groups are age 71 (127 reports), age 73 (108 reports), age 74 (102 reports). These demographics reflect reporting patterns and may not represent the full patient population.
Out of 4,222 classified reports for VERAPAMIL HYDROCHLORIDE:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
Verapamil Hydrochloride can cause significant drug interactions and should be used with caution, especially with other cardiovascular medications.
If you are taking Verapamil Hydrochloride, here are important things to know. The most commonly reported side effects include dyspnoea, nausea, drug interaction, dizziness, hypotension. While many of these may be mild and temporary, you should contact your healthcare provider if any symptoms are severe or persistent. Monitor patients for signs of cardiovascular issues, especially bradycardia and arrhythmias. Be cautious when combining Verapamil Hydrochloride with other medications to avoid drug interactions. If you experience a serious adverse reaction, seek emergency medical attention immediately or call 911. You can report side effects to the FDA's MedWatch program at 1-800-FDA-1088.
The FDA closely monitors Verapamil Hydrochloride due to its high rate of serious adverse events, particularly in older adults.
The FDA has received approximately 13,321 adverse event reports associated with Verapamil Hydrochloride. These reports come from healthcare professionals, consumers, and manufacturers through the FDA Adverse Event Reporting System (FAERS). Note that the number of reports does not directly indicate the frequency of side effects, as adverse events are voluntarily reported and may be underrepresented.
The most frequently reported adverse events for Verapamil Hydrochloride include Dyspnoea, Nausea, Drug Interaction, Dizziness, Hypotension. By volume, the top reported reactions are: Dyspnoea (355 reports), Nausea (341 reports), Drug Interaction (316 reports). These figures reflect FDA adverse event reports and may not represent the true incidence rate of these side effects in all patients taking Verapamil Hydrochloride.
Out of 4,222 classified reports, 3,812 (90.3%) were classified as serious and 410 as non-serious. The FDA classifies an event as "serious" if it results in death, hospitalization, disability, or other medically significant outcomes. A higher serious-event ratio warrants closer attention but does not necessarily mean the drug is unsafe.
Adverse event reports for Verapamil Hydrochloride break down by patient sex as follows: Female: 2,200, Male: 1,461, Unknown: 24. This distribution reflects reporting patterns rather than actual risk differences between groups. Reporting rates can be influenced by prescribing patterns, disease demographics, and reporting behavior.
The most frequently reported age groups for Verapamil Hydrochloride adverse events are: age 71: 127 reports, age 73: 108 reports, age 74: 102 reports, age 78: 101 reports, age 68: 88 reports. Age-related reporting patterns can reflect both the demographics of the patient population and potential age-related susceptibility to certain side effects.
The primary manufacturer associated with Verapamil Hydrochloride adverse event reports is Lannett Company, Inc.. Multiple manufacturers may produce generic versions of this drug. The manufacturer listed reflects the most frequently reported brand in FDA adverse event data.
Beyond the most common reactions, other reported adverse events for Verapamil Hydrochloride include: Fatigue, Diarrhoea, Cough, Abdominal Pain, Asthenia. Less common side effects can still be clinically significant. Patients should report any unusual symptoms to their healthcare provider.
You can report adverse events from Verapamil Hydrochloride to the FDA through their MedWatch program at www.fda.gov/medwatch, by calling 1-800-FDA-1088, or by completing Form FDA 3500. Healthcare professionals, consumers, and manufacturers can all submit reports. Reporting helps the FDA monitor drug safety after approval.
Verapamil Hydrochloride has a safety concern score of 85 out of 100 (high concern). This score is calculated from the ratio of serious to non-serious adverse events, the diversity of reported reactions, and the overall volume of reports relative to usage. High incidence of serious reactions such as respiratory issues, cardiovascular events, and drug interactions.
Key safety signals identified in Verapamil Hydrochloride's adverse event data include: High rate of serious adverse events (90.3%). Multiple cardiovascular issues including arrhythmias, bradycardia, and heart rate changes. Falls and syncope reported frequently, suggesting potential for falls and dizziness. These signals are derived from patterns in FDA reports and should be discussed with a healthcare provider for personalized assessment.
Verapamil Hydrochloride can cause significant drug interactions and should be used with caution, especially with other cardiovascular medications. Always inform your healthcare provider about all medications, supplements, and over-the-counter drugs you are taking before starting Verapamil Hydrochloride.
Monitor patients for signs of cardiovascular issues, especially bradycardia and arrhythmias. Be cautious when combining Verapamil Hydrochloride with other medications to avoid drug interactions.
Verapamil Hydrochloride has 13,321 adverse event reports on file with the FDA. A significant number of reports involve falls and syncope, indicating potential risk of falls and dizziness. The volume of reports for Verapamil Hydrochloride reflects both the drug's usage level and the vigilance of the reporting community.
The FDA closely monitors Verapamil Hydrochloride due to its high rate of serious adverse events, particularly in older adults. For the most current regulatory information, check the FDA's drug labeling database or consult your pharmacist.
Explore other medications manufactured by Lannett Company, Inc. and compare their safety profiles:
The following drugs share commonly reported adverse reactions with VERAPAMIL HYDROCHLORIDE:
Drugs related to VERAPAMIL HYDROCHLORIDE based on therapeutic use, drug class, or shared indications: